Mature results from EORTC 22033: Implications of inferior results with monotherapy for grade 2 gliomas

Temozolomide versus radiotherapy as first-line therapy for low-grade glioma: mature results of a randomized phase III trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU)

10.1200/jco-25-02735 · 2026

Comprehensive genomic analysis in NRG oncology/RTOG 9802: a phase III trial of radiation versus radiation plus procarbazine, lomustine (CCNU), and vincristine in high-risk low-grade glioma

10.1200/jco.19.02983 · 2020

Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trial

10.1016/s1470-2045(25)00614-x · 2026

Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study

10.1016/s1470-2045(16)30305-9 · 2016

Impact of radiation target volume on health-related quality of life in patients with low-grade glioma in the 2-year period post treatment: a secondary analysis of the EORTC 22033-26033

10.1016/j.ijrobp.2019.01.003 · 2019

Evaluation of the hippocampal normal tissue complication model in a prospective cohort of low grade glioma patients—an analysis within the EORTC 22033 clinical trial

10.3389/fonc.2019.00991 · 2019

Memory in low-grade glioma patients treated with radiotherapy or temozolomide: a correlative analysis of EORTC study 22033-26033

10.1093/neuonc/noaa252 · 2021